Edgewise Therapeutics
EWTX
71 hedge funds and large institutions have $523M invested in Edgewise Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 4 closing their positions.
325% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 4
257% more capital inflows, than outflows
Capital inflows: $64.2M | Capital outflows: $18M
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
22% more funds holding
Funds holding: 58 → 71 (+13)
6.89% more ownership
Funds ownership: 102.09% → 108.98% (+6.9%)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$14.4M |
| 2 |
EcoR1 Capital
San Francisco,
California
|
+$13.9M |
| 3 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$8.53M |
| 4 |
DAFNA Capital Management
Los Angeles,
California
|
+$4.59M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Logos Global Management
San Francisco,
California
|
-$8.19M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.39M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.25M |
| 4 |
Janus Henderson Group
London,
|
-$1.2M |
| 5 |
Woodline Partners
San Francisco,
California
|
-$550K |
EWTX Hedge Fund Activity: Q1 2022 in Review
71 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2022, worth a combined $523M — down 32% from $769M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EWTX positions and 4 closed out — a net gain of 13 holders — while 25 added to existing stakes and 18 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $14.4M. The largest seller was Logos Global Management, cutting an estimated $8.19M.
- 71 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2022, up from 58 in Q4 2021.
- Funds reported $523M of Edgewise Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
- 17 funds opened new Edgewise Therapeutics positions in Q1 2022 and 4 closed out, a net change of +13 holders.
- The largest Edgewise Therapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $14.4M added.
- The largest Edgewise Therapeutics seller in Q1 2022 was Logos Global Management, an estimated $8.19M sold.
Based on aggregated 13F filings for Q1 2022.